CD4 and B-cell non-Hodgkin lymphoma: However, recent antigen-presentation profiling work is revealing that B cell lymphomas including CLL can present immunoglobulin neoantigens (15), with preferential MHC-II presentation that has implications for promoting the cytolytic TH1 differentiation of neoantigen-specific CD4+ T cells with immunotherapy, as has been demonstrated in solid cancer (168).